Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paxil Generics Grab 65% Of New Scripts; Apotex May Sue Over Par/GSK Deal

Executive Summary

Generics of GlaxoSmithKline's antidepressant Paxil have captured 65% of the market for new paroxetine prescriptions, Apotex said

You may also be interested in...



GSK Is Not Aventis’ “White Knight”; 2004 Will Be A Transition Year

GlaxoSmithKline will not make a "white knight" bid for Aventis, GSK said during its Feb. 12 year-end earnings presentation

GSK Is Not Aventis’ “White Knight”; 2004 Will Be A Transition Year

GlaxoSmithKline will not make a "white knight" bid for Aventis, GSK said during its Feb. 12 year-end earnings presentation

Synthon Pexeva To Launch At 20% Discount To Generic Paxil; GSK Suit Settled

Synthon will launch Pexeva (paroxetine mesylate) during the first half of the year at a 20% discount to generic versions of Paxil (paroxetine hydrochloride)

Related Content

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel